Alovudine F-18
- Generic Name
- Alovudine F-18
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13FN2O4
- CAS Number
- 287114-80-1
- Unique Ingredient Identifier
- 2X1K91UT6N
- Background
Alovudine F-18 is under investigation in clinical trial NCT02819024 (Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography).
- Associated Conditions
- -
- Associated Therapies
- -
Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT03613259
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 74
- Registration Number
- NCT03422731
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 28
- Registration Number
- NCT01928186
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT01713049
- Locations
- 🇨🇳
Department of Medical Imaging NTUH, Taipei, Taiwan
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 85
- Registration Number
- NCT01480583
- Locations
- 🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸NCI, Rockville, Maryland, United States
FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00880074
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00633958
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 90
- Registration Number
- NCT00572728
- Locations
- 🇺🇸
Morton Plant Hospital, Clearwater, Florida, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.